The 340B Program Is Not Disappearing, but Its Economics May Change Fast

Pharmacists have good reason to worry about the future of the 340B Drug Pricing Program. But the immediate danger is not repeal. The greater risk is that federal policy will preserve the statutory program while reducing its financial value and making participation harder to administer.

Congress requires participating manufacturers to offer covered outpatient drugs to eligible providers at or below a statutory ceiling price. The law also prohibits duplicate Medicaid discounts and the transfer of discounted drugs to people who are not patients of the covered entity.¹ That mandate remains in force.

The operational model may change sharply. HRSA’s revised rebate pilot would permit approved manufacturers to charge wholesale acquisition cost initially and provide the discount through a later payment. The pilot covers selected Medicare negotiation drugs for the 2026 and 2027 price-applicability years, regardless of payer. Manufacturers must pay or document the denial of a complete claim within ten calendar days. Covered entities generally receive forty-five days after dispensing to submit the required data.²

The D.C. Circuit has confirmed that federal law permits rebates, but manufacturers cannot impose them unilaterally. The Secretary must authorize the mechanism first.³ HRSA has now supplied that authorization pathway through the revised pilot.

For pharmacists, the ten-day requirement does not eliminate risk. The clock restarts when a manufacturer finds submitted data incomplete. The rebate goes to the covered entity, while a contract pharmacy may still absorb inventory expense, data work, reconciliation duties, or delayed compensation under its agreement. ASHP has also identified unresolved questions about inconsistent manufacturer procedures, data governance, denial oversight, and enforcement.⁴

A second threat comes from Medicare reimbursement. CMS proposes paying ASP minus 33.4 percent for affected drugs beginning in 2027. CMS estimates that the change would reduce Original Medicare drug payments by $4.55 billion and beneficiary payments by $1.15 billion during the first year.⁵

The Supreme Court invalidated earlier differential payments because HHS had not conducted the acquisition-cost survey required by Medicare law.⁶ CMS conducted a new survey before issuing the current proposal. Any challenge will therefore confront a different administrative record.

Congress is also considering reform rather than abolition. The bipartisan SUSTAIN 340B Act would protect contract-pharmacy use, require point-of-purchase discounts, create a claims clearinghouse, and end the rebate pilot within one year. It would also impose stronger patient, reporting, audit, and financial-assistance requirements.⁷

The program is unlikely to vanish soon. But its familiar economics may. Pharmacists and covered entities should prepare for a system that demands more capital, cleaner claims data, tighter contracts, and documented proof that program savings support patient care.

Read the companion implementation analysis of HRSA’s revised rebate pilot, review areas of experience, or explore the Court Cases of Interest tracker.

This post is for general informational purposes only and is not legal advice. It relies solely on public agency materials and published decisions. Reading it does not create an attorney-client relationship.